The Role of HNKs in the Antidepressant Effect of... — Clinical Trial Details

Double-blind, randomised, parallel study in participants with current major depressive episodes comparing three single IV ketamine doses (0.3, 0.5, 0.7 mg/kg) to evaluate serum hydroxynorketamine (HNK) in relation to clinical change on HDRS, BDI and POMS.

MRI measures of glutamate and GABA are acquired before and during ketamine treatment to test whether acute neurotransmitter changes mediate antidepressant effects; primary purpose listed as basic science.

Inclusion Criteria:
Current major depressive episode (MDE) as part of major depressive disorder (MDD). May be psychiatric medication-free or, if on psychiatric medications, not responding adequately.
Off all psychotropic and other types of drugs likely to interact with glutamate for at least 14 days before starting the study OR likely able to tolerate a medication washout.
Female subjects of child-bearing potential must be using an acceptable method of birth control throughout the study.

Exclusion Criteria:
Lifetime history of schizophrenia, schizoaffective illness, bipolar disorder, or psychosis.
First-degree relative with schizophrenia, schizoaffective disorder, or bipolar disorder if the subject is less than 33 years old.
Significant uncontrolled physical illness.
Electroconvulsive therapy (ECT) within the last 3 months for current MDE.
Pregnancy or plans to conceive during the course of study participation.
Heart pacemaker, body implant or other metal in body.
Neurological disease or prior head trauma with evidence of cognitive impairment.
Claustrophobia sufficient to preclude MRI.
Prior ineffective trial of, or adverse effect to, ketamine.
IV drug use or history of ketamine use as a recreational drug ≥ 2 times or an adverse reaction to ketamine; any other drug or alcohol dependence within past 6 months.

Company

Product

Legal

The Role of HNKs in the Antidepressant Effect of Ketamine

Detailed Description

Study Protocol

Preparation

Dosing

Locations

Integration

Study Arms & Interventions

Ketamine 0.3 mg/kg

Interventions

Ketamine 0.5 mg/kg

Interventions

Ketamine 0.7 mg/kg

Interventions

Participants

Inclusion Criteria

Exclusion Criteria

Study Details

Study Team

Sponsors & Collaborators